Chocolate Cardiovascular Steatotic Liver Disease Risk Factors: What the Evidence Says

Quick Answer

Chocolate Cardiovascular Steatotic Liver Disease Risk Factors has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 narrative review, 1 observational study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• MetS is a multifactorial condition, with its primary indicators including obesity, hypertension, dyslipidemia, insulin resistance, and hyperglycemia; i.e., a patient who possesses at least 3 of the following parameters is designated with MetS: glucose intolerance, increased levels of triglycerides, augmented waist circumference, low levels of high-density lipoprotein cholesterol (HDL-c), and hypertension. [Tomaru Júlia Mayumi (2026); evidence level 3]
• It is possible to develop a close relationship with MetS, metabolic dysfunction-associated steatotic liver disease (MASLD), and CVD. [Tomaru Júlia Mayumi (2026); evidence level 3]
• Metabolic dysfunction-associated steatotic liver disease (MASLD) is a newly proposed definition characterized by hepatic lipid accumulation in the presence of metabolic risk factors. [Emami Omid (2025); evidence level 3]
• The clinical implications of MASLD extend beyond hepatic dysfunction, as it is strongly associated with increased risks of cardiovascular disease, type 2 diabetes mellitus, liver-related diseases, cancers, chronic kidney disease, and overall mortality. [Emami Omid (2025); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For chocolate cardiovascular steatotic liver disease risk factors, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Tomaru Júlia Mayumi (2026). Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors. DOI: 10.3390/nu18040636. PMCID: PMC12943539. PMID: 41754152. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12943539/
• Emami Omid (2025). Ultra-processed food consumption and the risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD): a five-year prospective cohort study in Iranian adults. DOI: 10.1186/s41043-025-01150-4. PMCID: PMC12648998. PMID: 41291958. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC12648998/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.